Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Epithelial TNF Receptor Signaling Promotes Mucosal Repair in Inflammatory Bowel Disease.

Bradford EM, Ryu SH, Singh AP, Lee G, Goretsky T, Sinh P, Williams DB, Cloud AL, Gounaris E, Patel V, Lamping OF, Lynch EB, Moyer MP, De Plaen IG, Shealy DJ, Yang GY, Barrett TA.

J Immunol. 2017 Sep 1;199(5):1886-1897. doi: 10.4049/jimmunol.1601066. Epub 2017 Jul 26.

PMID:
28747340
2.

Role of the inflammatory response in the hemorrhagic syndrome induced by the hemolymph of the caterpillar Lonomia achelous.

Taylor P, Salazar E, Barrios M, Salazar AM, Abad MJ, Urdanibia I, Shealy D, Arocha-Piñango CL, Guerrero B.

Toxicon. 2016 Oct;121:77-85. doi: 10.1016/j.toxicon.2016.08.018. Epub 2016 Aug 26.

PMID:
27576063
3.

Divergent gene activation in peripheral blood and tissues of patients with rheumatoid arthritis, psoriatic arthritis and psoriasis following infliximab therapy.

Rosenberg A, Fan H, Chiu YG, Bolce R, Tabechian D, Barrett R, Moorehead S, Baribaud F, Liu H, Peffer N, Shealy D, Schwarz EM, Ritchlin CT.

PLoS One. 2014 Oct 21;9(10):e110657. doi: 10.1371/journal.pone.0110657. eCollection 2014.

4.

Anti-tumor necrosis factor α prevents bowel fibrosis assessed by messenger RNA, histology, and magnetization transfer MRI in rats with Crohn's disease.

Adler J, Rahal K, Swanson SD, Schmiedlin-Ren P, Rittershaus AC, Reingold LJ, Brudi JS, Shealy D, Cai A, McKenna BJ, Zimmermann EM.

Inflamm Bowel Dis. 2013 Mar-Apr;19(4):683-90. doi: 10.1097/MIB.0b013e3182802c32.

PMID:
23429466
5.

Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders.

Benson JM, Peritt D, Scallon BJ, Heavner GA, Shealy DJ, Giles-Komar JM, Mascelli MA.

MAbs. 2011 Nov-Dec;3(6):535-45. doi: 10.4161/mabs.3.6.17815. Epub 2011 Nov 1. Review.

6.

Refracting the k-function: Stavroudis's solution to the eikonal equation for multielement optical systems.

Hoffnagle JA, Shealy DL.

J Opt Soc Am A Opt Image Sci Vis. 2011 Jun 1;28(6):1312-21. doi: 10.1364/JOSAA.28.001312.

PMID:
21643418
7.

Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus.

Villanueva E, Yalavarthi S, Berthier CC, Hodgin JB, Khandpur R, Lin AM, Rubin CJ, Zhao W, Olsen SH, Klinker M, Shealy D, Denny MF, Plumas J, Chaperot L, Kretzler M, Bruce AT, Kaplan MJ.

J Immunol. 2011 Jul 1;187(1):538-52. doi: 10.4049/jimmunol.1100450. Epub 2011 May 25.

8.

Evaluation of an anti-tumor necrosis factor therapeutic in a mouse model of Niemann-Pick C liver disease.

Vincent M, Sayre NL, Graham MJ, Crooke RM, Shealy DJ, Liscum L.

PLoS One. 2010 Sep 23;5(9):e12941. doi: 10.1371/journal.pone.0012941.

9.

Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.

Shealy DJ, Cai A, Staquet K, Baker A, Lacy ER, Johns L, Vafa O, Gunn G 3rd, Tam S, Sague S, Wang D, Brigham-Burke M, Dalmonte P, Emmell E, Pikounis B, Bugelski PJ, Zhou H, Scallon BJ, Giles-Komar J.

MAbs. 2010 Jul-Aug;2(4):428-39. Epub 2010 Jul 1.

10.

TNF-alpha drives remodeling of blood vessels and lymphatics in sustained airway inflammation in mice.

Baluk P, Yao LC, Feng J, Romano T, Jung SS, Schreiter JL, Yan L, Shealy DJ, McDonald DM.

J Clin Invest. 2009 Oct;119(10):2954-64. doi: 10.1172/JCI37626. Epub 2009 Sep 14.

11.

Tumor necrosis factor deficiency inhibits mammary tumorigenesis and a tumor necrosis factor neutralizing antibody decreases mammary tumor growth in neu/erbB2 transgenic mice.

Warren MA, Shoemaker SF, Shealy DJ, Bshar W, Ip MM.

Mol Cancer Ther. 2009 Sep;8(9):2655-63. doi: 10.1158/1535-7163.MCT-09-0358. Epub 2009 Sep 15.

12.

Evaluation of anti-IL-6 monoclonal antibody therapy using murine type II collagen-induced arthritis.

Liang B, Song Z, Wu B, Gardner D, Shealy D, Song XY, Wooley PH.

J Inflamm (Lond). 2009 Apr 15;6:10. doi: 10.1186/1476-9255-6-10.

13.

Wavefront and caustics of a plane wave refracted by an arbitrary surface.

Shealy DL, Hoffnagle JA.

J Opt Soc Am A Opt Image Sci Vis. 2008 Sep;25(9):2370-82.

PMID:
18758565
14.

Elucidating bone marrow edema and myelopoiesis in murine arthritis using contrast-enhanced magnetic resonance imaging.

Proulx ST, Kwok E, You Z, Papuga MO, Beck CA, Shealy DJ, Calvi LM, Ritchlin CT, Awad HA, Boyce BF, Xing L, Schwarz EM.

Arthritis Rheum. 2008 Jul;58(7):2019-29. doi: 10.1002/art.23546.

15.
16.

Anti-TNF antibodies: lessons from the past, roadmap for the future.

Shealy DJ, Visvanathan S.

Handb Exp Pharmacol. 2008;(181):101-29. Review.

PMID:
18071943
17.

Longitudinal assessment of synovial, lymph node, and bone volumes in inflammatory arthritis in mice by in vivo magnetic resonance imaging and microfocal computed tomography.

Proulx ST, Kwok E, You Z, Papuga MO, Beck CA, Shealy DJ, Ritchlin CT, Awad HA, Boyce BF, Xing L, Schwarz EM.

Arthritis Rheum. 2007 Dec;56(12):4024-37.

18.

MRI and quantification of draining lymph node function in inflammatory arthritis.

Proulx ST, Kwok E, You Z, Beck CA, Shealy DJ, Ritchlin CT, Boyce BF, Xing L, Schwarz EM.

Ann N Y Acad Sci. 2007 Nov;1117:106-23. Epub 2007 Jul 23.

PMID:
17646265
19.

Laser beam shaping profiles and propagation.

Shealy DL, Hoffnagle JA.

Appl Opt. 2006 Jul 20;45(21):5118-31.

PMID:
16826250
20.

Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling.

Yang G, Volk A, Petley T, Emmell E, Giles-Komar J, Shang X, Li J, Das AM, Shealy D, Griswold DE, Li L.

Cytokine. 2004 Dec 21;28(6):224-32.

PMID:
15566951
21.

Induction of dendritic cell maturation by IL-18.

Li J, Mbow ML, Sun L, Li L, Yang G, Griswold DE, Schantz A, Shealy DJ, Goletz TJ, Wan J, Peritt D.

Cell Immunol. 2004 Feb;227(2):103-8.

PMID:
15135292
22.

Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis.

Fleischmann R, Shealy D.

Mol Interv. 2003 Sep;3(6):310-8. Review. No abstract available.

PMID:
14993463
23.

Coming of age: anti-cytokine therapies.

Song XY, Torphy TJ, Griswold DE, Shealy D.

Mol Interv. 2002 Feb;2(1):36-46. Review.

PMID:
14993360
24.

An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors.

Scott KA, Moore RJ, Arnott CH, East N, Thompson RG, Scallon BJ, Shealy DJ, Balkwill FR.

Mol Cancer Ther. 2003 May;2(5):445-51.

25.

Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice.

Shealy DJ, Wooley PH, Emmell E, Volk A, Rosenberg A, Treacy G, Wagner CL, Mayton L, Griswold DE, Song XY.

Arthritis Res. 2002;4(5):R7. Epub 2002 Jun 28.

26.

Binding and functional comparisons of two types of tumor necrosis factor antagonists.

Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C.

J Pharmacol Exp Ther. 2002 May;301(2):418-26.

27.

TNF receptor 1, IL-1 receptor, and iNOS genetic knockout mice are not protected from anthrax infection.

Kalns J, Scruggs J, Millenbaugh N, Vivekananda J, Shealy D, Eggers J, Kiel J.

Biochem Biophys Res Commun. 2002 Mar 22;292(1):41-4.

PMID:
11890668
28.

Effects of 2 different anti-tumor necrosis factor-alpha agents in a primate model of subcutaneous abscess formation.

Song XY, Fox F, Gallo MA, Rosenberg A, Jordan R, Shealy D, Wagner C.

J Infect Dis. 2002 Jan 15;185(2):204-13. Epub 2002 Jan 3.

PMID:
11807694
29.

Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease.

Cornillie F, Shealy D, D'Haens G, Geboes K, Van Assche G, Ceuppens J, Wagner C, Schaible T, Plevy SE, Targan SR, Rutgeerts P.

Aliment Pharmacol Ther. 2001 Apr;15(4):463-73.

30.
31.

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ.

Gastroenterology. 1999 Jan;116(1):22-8.

PMID:
9869598
32.

A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease.

Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D, Targan SR.

J Immunol. 1997 Dec 15;159(12):6276-82.

PMID:
9550432
33.

Correlation of environmental carbaryl measurements with serum and urinary 1-naphthol measurements in a farmer applicator and his family.

Shealy DB, Barr JR, Ashley DL, Patterson DG Jr, Camann DE, Bond AE.

Environ Health Perspect. 1997 May;105(5):510-3.

34.

Development and testing of a holographic projection system.

Jiang W, Shealy DL, Baker KM.

Appl Opt. 1996 Oct 20;35(30):5994-8. doi: 10.1364/AO.35.005994.

PMID:
21127614
35.

Identification of a major human urinary metabolite of alachlor by LC-MS/MS.

Driskell WJ, Hill RH Jr, Shealy DB, Hull RD, Hines CJ.

Bull Environ Contam Toxicol. 1996 Jun;56(6):853-9. No abstract available.

PMID:
8661877
36.

Pesticide residues in urine of adults living in the United States: reference range concentrations.

Hill RH Jr, Head SL, Baker S, Gregg M, Shealy DB, Bailey SL, Williams CC, Sampson EJ, Needham LL.

Environ Res. 1995 Nov;71(2):99-108.

PMID:
8977618
37.

Determination of pesticide metabolites in human urine using an isotope dilution technique and tandem mass spectrometry.

Hill RH Jr, Shealy DB, Head SL, Williams CC, Bailey SL, Gregg M, Baker SE, Needham LL.

J Anal Toxicol. 1995 Sep;19(5):323-9.

PMID:
7500620
38.

Optical analysis of an ultra-high resolution two-mirror soft x-ray microscope.

Shealy DL, Wang C, Hoover RB.

J Xray Sci Technol. 1995 Jan 1;5(1):1-19. doi: 10.3233/XST-1995-5101.

PMID:
21307473
39.

The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo.

Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe DS, Probert L, Kollias G, Ghrayeb J, Vilcek J, Daddona PE.

Cytokine. 1995 Jan;7(1):15-25.

PMID:
7538333
40.

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.

Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, et al.

Mol Immunol. 1993 Nov;30(16):1443-53.

PMID:
8232330
41.

Design of gradient-index lens systems for laser beam reshaping.

Wang C, Shealy DL.

Appl Opt. 1993 Sep 1;32(25):4763-9. doi: 10.1364/AO.32.004763.

PMID:
20830143
42.

Human monoclonal antibody HA-1A binds to endotoxin via an epitope in the lipid A domain of lipopolysaccharide.

Bogard WC Jr, Siegel SA, Leone AO, Damiano E, Shealy DJ, Ely TM, Frederick B, Mascelli MA, Siegel RC, Machielse B, et al.

J Immunol. 1993 May 15;150(10):4438-49.

PMID:
7683319
43.

Reactivity of the human antiendotoxin immunoglobulin M monoclonal antibody HA-1A with lipopolysaccharides from rough and smooth gram-negative organisms.

Mascelli MA, Frederick B, Ely T, Neblock DS, Shealy DJ, Pak KY, Daddona PE.

Infect Immun. 1993 May;61(5):1756-63.

44.

Differential equation design of finite-conjugate reflective systems.

Wang C, Shealy DL.

Appl Opt. 1993 Mar 1;32(7):1179-88. doi: 10.1364/AO.32.001179.

PMID:
20820251
45.

Rapid infarct imaging with a technetium-99m-labeled antimyosin recombinant single-chain Fv: evaluation in a canine model of acute myocardial infarction.

Nedelman MA, Shealy DJ, Boulin R, Brunt E, Seasholtz JI, Allen IE, McCartney JE, Warren FD, Oppermann H, Pang RH, et al.

J Nucl Med. 1993 Feb;34(2):234-41.

46.

Pharmacokinetics of indium-111 labeled 10-3D2 antibreast-tumor antibody in patients.

Hnatowich DJ, Rusckowski M, Siebecker DA, Gionet M, Mardirossian G, Bushe HS, Roy S, Mattis JA, Shealy D, Griffin TW, et al.

J Nucl Biol Med. 1992 Jan-Mar;36(1):7-13.

PMID:
1450229
47.

Optimization of three- and four-element lens systems by minimizing the caustic surfaces.

Al-Ahdali IH, Shealy DL.

Appl Opt. 1990 Nov 1;29(31):4551-9. doi: 10.1364/AO.29.004551.

PMID:
20577432
48.

Formula for the rms blur circle radius of Wolter telescope based on aberration theory.

Shealy DL, Saha TT.

Appl Opt. 1990 Jun 1;29(16):2433-9. doi: 10.1364/AO.29.002433.

PMID:
20563186
49.

Formula for the rms blur circle radius of Wolter telescope based on aberration theory.

Shealy DL, Saha TT.

Appl Opt. 1990 Jun 1;29(16):2432. doi: 10.1364/AO.29.002432. No abstract available.

PMID:
20563185
50.

Caustic merit function for optical design.

Kassim AM, Shealy DL, Burkhard DG.

Appl Opt. 1989 Feb 1;28(3):601-6. doi: 10.1364/AO.28.000601.

PMID:
20548526

Supplemental Content

Loading ...
Support Center